Shawn Harriman, Ph.D., is Chief Development Officer, Head of Translational Sciences at Skylark Bio. He brings over 27 years of experience working in cross-functional teams bridging clinical, pre-clinical and drug discovery. Dr. Harriman has worked across multiple therapeutic areas and has been involved in over 30 IND filings and four drug approvals. He has extensive experience with a diverse set of modalities, including gene therapy, and interacting with global regulatory bodies including, the CBER and CDER divisions of the FDA, EMA, MHRA, PMDA, and most recently with the Chinese regulatory agency, NMPA.

Prior to joining Skylark he was Chief Development Officer, Head of Research and Development, for Frontera Therapeutics responsible for the development of AAV based gene therapies for Ophthalmology, Hematology, Neuromuscular and Metabolic Disease indications. He served as Senior Vice President for Pyxis Oncology, Head of Nonclinical Development, where he was responsible for the advancement of immuno-oncology and antibody-drug conjugate-based oncology programs through preclinical development to IND stage and into clinic. Lastly, he served as Vice President at Sarepta Therapeutics, Head of Translational Sciences, where he was a key contributor in the company obtaining accelerated FDA approval of two medicinal products, Vyondys and Amondys for Duchenne muscular dystrophy (DMD), and for the advancement of AAV based gene therapies for DMD and other rare neuromuscular diseases.

Dr. Harriman received a B.S. in Zoology and an M.S. in Pharmaceutical Sciences from the University of Rhode Island. Dr. Harriman received his Ph.D. in Medicinal Chemistry from the University of Kansas and completed his postdoctoral research at the Massachusetts Institute of Technology.